There is inherent value in early science or platform technology that promises to generate multiple clinical programmes, often targeting a range of opportunities from large patient groups with an established standard of care, to orphan populations with high unmet need. The decision to enter the clinic – with which asset, for which indication, at which doses to ultimately treat which patients – is of paramount importance as cash burn and risk increase exponentially.
Strategic vision needs to envisage the product through to market, not just to an exit or partnering event mid-stage, to drive increasingly upward valuation and create leverage and optionality for the company. Key considerations & questions include:
Cello Health works with many emerging biotech companies to prioritise pipeline portfolios and define pathways to value inflection. Often, these programmes are at pre-clinical to early clinical development (Phase I-Phase 2a) so our advice contributes to shaping the early development programme, maximising the fruitful deployment of costly capital and the potential for clinical and commercial success. Output typically includes a definition of therapeutic strategy and best transaction model going forward.
“Thank you for sending the final deliverable…The data are so rich – we will likely be browsing through that trove for some time. Thank you, once again, for accommodating a tight timeline at the onset of the project…. Looking forward to next engagements!”
